AVROBIO, Inc. (AVRO)

NASDAQ: AVRO · IEX Real-Time Price · USD
1.270
+0.010 (0.79%)
Mar 28, 2024, 1:28 PM EDT - Market open

Company Description

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.

Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease.

The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome.

The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

AVROBIO, Inc.
AVROBIO logo
Country United States
Founded 2015
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Erik John Ostrowski M.B.A.

Contact Details

Address:
100 Technology Square, 6th Floor
Cambridge, Massachusetts 02139
United States
Phone 617.914.8420
Website avrobio.com

Stock Details

Ticker Symbol AVRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001681087
CUSIP Number 05455M100
ISIN Number US05455M1009
Employer ID 81-0710585
SIC Code 2836

Key Executives

Name Position
Erik John Ostrowski M.B.A. President, Interim Chief Executive Officer, Chief Financial Officer and Treasurer
Dr. Azadeh Golipour Ph.D. Chief Technology Officer
Dr. Essra Ridha FFPM, M.D. Chief Medical Officer
Jeffrey Medin Ph.D. Scientific Founder
Steven N. Avruch J.D. Chief Legal Officer and Secretary
Scott Gottesman Vice President of Human Resource
Kirsten Dupuis Chief of Staff

Latest SEC Filings

Date Type Title
Mar 26, 2024 S-4/A Filing
Mar 14, 2024 10-K Annual Report
Feb 23, 2024 SCHEDULE 13G Filing
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 S-4 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 30, 2024 425 Filing
Jan 30, 2024 425 Filing